| Identification | Back Directory | [Name]
2-Pyridinecarboxamide, 4-[4-[(3-methoxybenzoyl)amino]phenoxy]-N-methyl- | [CAS]
1246566-47-1 | [Synonyms]
YLT192
YLT-192
YLT 192
2-Pyridinecarboxamide, 4-[4-[(3-methoxybenzoyl)amino]phenoxy]-N-methyl- | [Molecular Formula]
C21H19N3O4 | [MOL File]
1246566-47-1.mol | [Molecular Weight]
377.39 |
| Hazard Information | Back Directory | [Description]
YLT192 is an orally active and bioavailable inhibitor of VEGFR2 signaling with potent antiangiogenic activity and antitumor efficacy. | [Uses]
YLT192 is an orally active and highly bioavailable VEGFR2 inhibitor with potent anti-angiogenic activity and anti-tumor efficacy. YLT192 significantly inhibited the kinase activity of VEGFR2 and inhibited the proliferation, migration, invasion and tube formation of human umbilical cord vascular endothelial cells. YLT192 also inhibited VEGF-induced VEGFR2 phosphorylation and its downstream signaling regulators. YLT192 also showed the ability to inhibit angiogenesis in vivo in zebrafish embryo models and alginate-coated tumor cell experiments. YLT192 can directly inhibit the proliferation of cancer cells and induce their apoptosis[1]. | [References]
[1] YLT192, a novel, orally active bioavailable inhibitor of VEGFR2 signaling with potent antiangiogenic activity and antitumor efficacy in preclinical models |
|
|